Videos & Webinars - European Medical Journal

Continue

Video & Webinars

EMJ
Oncology
14 Oct 2015

Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b…
EMJ
Oncology
14 Oct 2015

ECC 2015: Post-diagnosis aspirin improves survival in gastrointestinal cancers

Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall…
EMJ
Oncology
14 Oct 2015

ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…
EMJ
Oncology
14 Oct 2015

ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…
EMJ
Oncology
14 Oct 2015

ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours

RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US…
EMJ
Oncology
14 Oct 2015

ECC 2015: Launch of the European Society for Paediatric Oncology (SIOPE) strategic plan

The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field…
EMJ
Oncology
14 Oct 2015

ECC 2015: News briefing chaired by Prof Martine Piccart

At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…
EMJ
Oncology
14 Oct 2015

ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…